Completed PHASE3 INTERVENTIONAL NCT00093093

Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment Naive (VISER2)

Randomized, Double-Blind, Multicenter Study to Compare the Safety and Efficacy of Viramidine to Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C

Sponsor: Bausch Health Americas, Inc.

Conditions Chronic Hepatitis C

Interventions Ribavirin Viramidine pegylated interferon alfa-2a

Updated 8 times since 2017 Last updated: Jun 21, 2012 Started: Jun 30, 2004 Primary completion: May 31, 2006 Completion: May 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Chronic Hepatitis C and is currently completed. Bausch Health Americas, Inc. leads this study, which shows 8 recorded versions since 2004 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2019 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jun 2019 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jun 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bausch Health Americas, Inc.

Data source: Bausch Health Americas, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adelaide, Australia , Annadale, United States , Atlanta, United States , Austin, United States , Badalona, Spain , Baltimore, United States , Barcelona, Spain , Birmingham, United Kingdom , Bradenton, United States , Buenos Aires, Argentina and 75 more locations